פרופ' יגאל דניאל [דני] כהן

סגל אקדמי בכיר בביה"ס לבריאות הציבור
ועדת מינויים יחידתית בדיקאנט ומנהל הפקולטה לרפואה
ביה"ס לבריאות הציבור סגל אקדמי בכיר
ניווט מהיר:
פרופ' יגאל דניאל [דני] כהן
טלפון פנימי: 03-6407081
פקס: 03-6409868


Professor, Epidemiology and Preventive Medicine, School of Public Health, Tel Aviv University

Chair, Middle East Consortium Middle East Consortium on Infectious Disease Surveillance (MECIDS)

Diana & Stanley Steyer Chair of Cancer Prevention and Control

Co-Director, Summer Institute of Advanced Epidemiology and Preventive Medicine, Tel Aviv University

Head, Tiberio Swartz Research Forum on Epidemiology of Infectious Diseases and Biosecurity



Professor Daniel (Dani) Cohen joined Tel Aviv University (TAU) for a full-time academic position in 2002 and has been a full Professor since 2007. Previously, he served in the Israel Defense Forces for many years and was the Director of the Infectious Diseases Research Institute in the Medical Corps. Prof. Cohen served as the Head of Tel Aviv University School of Public Health for 6 years, after serving 4 years as Chair of the Department of Epidemiology and Preventive Medicine. Prof. Cohen is currently the Diana & Stanley Steyer Chair of Cancer Prevention and Control.   


Prof. Cohen founded the Tiberio Swartz Forum on Epidemiology of Infectious Diseases and Biosecurity, a very active national and international stage for scientific communications and discussions in the field of infectious diseases and vaccines. Additionally, he is the co-founder and co-director of the Summer International Institute of Advanced Epidemiology and Preventive Medicine at TAU School of Public Health. He also serves as an executive board member and the current Chairperson of the Middle East Consortium for Infectious Diseases Surveillance (MECIDS) and acts on various national and international advisory boards in the field of infectious diseases and vaccines. Prof. Cohen has been a consultant for the World Health Organization (WHO) on several occasions. In November 2020 Prof. Cohen was appointed to the COVID-19 solidarity vaccines trial candidate vaccine prioritization WHO working group.


Prof. Cohen has supervised many graduate and post-graduate students. He has received several awards for his outstanding contribution to research and is the author of more than 230 original, peer-reviewed articles.


Click here to view Prof. Cohen's CV (Short Version).​


Research Interests

  • Epidemiology of infectious diseases
  • Vaccinology
  • Development and evaluation of enteric vaccines
  • Risk and protective host factors associated with enteric diseases and in particular: shigellosis
  • Study of the association between selected infectious agents (e.g. Helicobacter pylori, Human Papilloma Virus) and cancer 


Selected Publications

Click here for a complete list of Prof. Cohen's Peer-Reviewed Articles. 


Publications (from the last three years)


Bassal R, Wax M, Shirazi R, Shohat T, Cohen D, David D, Abu-Mouch S, Abu-Ghanem Y, Mendelson E, Ben-Ari Z, Mor O. Seroprevalence of hepatitis E virus in dromedary camels, Bedouins, Muslim Arabs and Jews in Israel, 2009-2017. Epidemiology and infection. 2019;147:5.

Bercovich S, Anis E, Kassem E, Rubinstein U, Ephros M, Cohen D, Muhsen K. Validation of parental reports of rotavirus vaccination of their children compared to the national immunization registry. Vaccine. 2019;37(21):2791-6.

Cohen D, Korin H, Bassal R, Markovich MP, Sivan Y, Goren S, Muhsen K. Burden and risk factors of Shigella sonnei shigellosis among children aged 0-59 months in hyperendemic communities in Israel. Int J Infect Dis. 2019;82:117-23.

Cohen D, Meron-Sudai S, Bialik A, Asato V, Goren S, Ariel-Cohen O, Reizis A, Hochberg A, Ashkenazi S. Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis. Human vaccines & immunotherapeutics. 2019;15(6):1401-8.

Cohen D, Muhsen K. Vaccines for enteric diseases. Human vaccines & immunotherapeutics. 2019;15(6):1205-14.

Danquah L, Sulo J, Mersini K, Bino S, Huda N, Adisasmito W, Soebandrio A, Karimuribo ED, Sindato C, Beda E, Rweyemamu M, Were W, Lutwama JJ, Yishai R, Cohen D, Thajeen J, Nyein SL, Oo MK, Libel M, Gresham L, Japra N, Burke C, Orefuwa E, Asquith P, Longuet C. Assessment of event based surveillance in cross border areas of six regional networks. Int J Infect Dis. 2019;79:36-.

Falup-Pecurariu O, Lixandru RI, Cojocaru E, Csutak K, Monescu V, Muhsen K, Falup-Pecurariu C, Cohen D. Shiga toxin producing Escherichia coli-associated diarrhea and hemolytic uremic syndrome in young children in Romania. Gut Pathogens. 2019;11(1):7.

Kaminski RW, Pasetti MF, Aguilar AO, Clarkson KA, Rijpkema S, Bourgeois AL, Cohen D, Feavers I, MacLennan CA. Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays. Clin Infect Dis. 2019;69:S596-S601.

Katz D, Ben-Chetrit E, Sherer SS, Cohen D, Muhsen K. Correlates of non-typhoidal Salmonella bacteraemia: A case-control study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2019;81:170-5.

Koren R, Bassal R, Shohat T, Cohen D, Mor O, Mendelson E, Lustig Y. Presence of Antibodies against Sindbis Virus in the Israeli Population: A Nationwide Cross-Sectional Study. Viruses-Basel. 2019;11(6):10.

Mani S, Toapanta FR, McArthur MA, Qadri F, Svennerholm AM, Devriendt B, Phalipon A, Cohen D, Sztein MB. Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development. Vaccine. 2019;37(34):4787-93.

Muhsen K, Kassem E, Rubenstein U, Goren S, Ephros M, Shulman LM, Cohen D. No evidence of an increase in the incidence of norovirus gastroenteritis hospitalizations in young children after the introduction of universal rotavirus immunization in Israel. Human vaccines & immunotherapeutics. 2019;15(6):1284-93.

Muhsen K, Reshef L, Ornoy A, Maya M, Gophna U, Cohen D. Gut microbiota at school age: Influential factors and associations with cognitive development: Preliminary results. Helicobacter. 2019;24:1.

Muhsen K, Sinnreich R, Merom D, Beer-Davidson G, Nassar H, Cohen D, Kark JD. Prevalence and determinants of serological evidence of atrophic gastritis among Arab and Jewish residents of Jerusalem: a cross-sectional study. BMJ open. 2019;9(1):e024689.

Muhsen K, Sinnreich R, Merom D, Nassar H, Cohen D, Kark JD. Helicobacter pylori infection, serum pepsinogens as markers of atrophic gastritis, and leukocyte telomere length: a population-based study. Hum Genomics. 2019;13:11.

Raz Y, Keinan-Boker L, Goren S, Soen-Grisaru G, Cohen D, Grisaru D. The effect of age at immigration on cervical cancer incidence: a population-based cohort study of 1 486 438 Israeli women. Int J Gynecol Cancer. 2019;29(3):492-6.

Rouach V, Goldshtein I, Buch A, Catane R, Chodick G, Stern N, Shalev V, Cohen D. The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women. Journal of bone oncology. 2019;16:7.

Sagie S, Naamnih W, Frej J, Cohen D, Alpert G, Muhsen K. Correlates of hospitalizations in internal medicine divisions among Israeli adults of different ethnic groups with hypertension, diabetes and cardiovascular diseases. PloS one. 2019;14(4):16.

Mazaba ML, Siziya S, Monze M, Cohen D. Epidemiology of acute rubella infection in Zambia during the pre-vaccination period (2005-2016) as a baseline for monitoring rubella epidemiology in the post-rubella vaccine introduction era. BMC infectious diseases. 2020;20(1):7.

Muhsen K, Na'amnih W, Adler A, Carmeli Y, Cohen D. Clostridium difficile-associated disease and Helicobacter pylori seroprevalence: A case-control study. Helicobacter. 2020;25(1):6.

Bassal R, Indenbaum V, Pando R, Levin T, Shinar E, Amichay D, Barak M, Ben-Dor A, Haim AB, Mendelson E, Cohen D, Shohat T. Seropositivity of measles antibodies in the Israeli population prior to the nationwide 2018 - 2019 outbreak. Hum Vaccin Immunother. 2020 Oct 29:1-5. 

Maor Y, Cohen D, Paran N, Israely T, Ezra V, Axelrod O, Shinar E, Izak M, Rahav G, Rahimi-Levene N, Bazofin BM, Gelman R, Dicker D, Brosh-Nissimov T, Megged O, Dahan D, Benov A, Paz A, Edward K, Moran A, Rogowski O, Sorkine P, Mayo A, Zimhony O, Chen J. Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. EClinicalMedicine. 2020 Sep;26

Na'amnih W, Carmeli Y, Asato V, Goren S, Adler A, Cohen D, Muhsen K. Enhanced Humoral Immune Responses against Toxin A and B of Clostridium difficile is Associated with a Milder Disease Manifestation. J Clin Med. 2020 Oct 10;9(10):3241.

Bassal R, Cohen D, Green MS, Keinan-Boker L. The Israel National Sera Bank: Methods, Representativeness, and Challenges. Int J Environ Res Public Health. 2021 Feb 25;18(5):2280.

Bassal R, Keinan-Boker L, Cohen D. A Significant Decrease in the Incidence of Shigellosis in Israel during COVID-19 Pandemic. Int J Environ Res Public Health. 2021 Mar 16;18(6):3070.

Izak M, Yahalom V, Maor Y, Zimhoni O, Cohen D, Chen J, Shinar E. COVID-19 - Blood groups, antibodies and convalescent plasma. [HEBREW]. Harefuah. 2021 Mar;160(3):139-143.

Cohen D, Atsmon J, Artaud C, Meron-Sudai S, Gougeon M-L, Bialik A, Goren S, Asato V, Ariel-Cohen O, Reizis A, Dorman A, Hoitink CWG, Westdijk J, Ashkenazi S, Sansonetti P, Mulard LA, Phalipon A.  Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose escalating, single-blind, randomised, placebo-controlled study. Lancet Inf Dis 2021 Apr;21(4):546-558.

Bassal R, Indenbaum V, Pando R, Levin T, Shinar E, Amichay D, Barak M, Ben-Dor A, Haim AB, Mendelson E, Cohen D, Shohat T. Seropositivity of measles antibodies in the Israeli population prior to the nationwide 2018 - 2019 outbreak. Hum Vaccin Immunother. 2021 May 4;17(5):1353-1357.

Chodick G, Tene L, Rotem RS, Patalon T, Gazit S, Ben-Tov A, Weil C, Goldshtein I, Twig G, Cohen D, Muhsen K. The effectiveness of the Two-Dose BNT162b2 vaccine: analysis of real-world data. Clin Infect Dis. 2021 May 17:ciab438. (Epub ahead of print)

Chisenga CC, Bosomprah S, Simuyandi M, Mwila-Kazimbaya K, Chilyabanyama ON, Laban NM, Bialik A, Asato V, Meron-Sudai S, Frankel G, Cohen D, Chilengi R. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study. PLoS One. 2021 May 27;16(5):e0252222.

Chodick G, Tene L, Patalon T, Gazit S, Ben Tov A, Cohen D, Muhsen K. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization. JAMA Netw Open. 2021 Jun 1;4(6):e2115985.

Izak M, Gendelman V, Bransburg-Zabary S, Stoyanov E, Gat R, Cohen D, Chen J, Maor Y, Benov A, Lev B, Zimhony O, Shinar E. Qualifying coronavirus disease 2019 convalescent plasma donors in Israel. Vox Sang. 2021 Jun 14. (Epub ahead of print)

Muhsen K, Schwaber MJ, Bishara J, Kassem E, Atamna A, Na'amnih W, Goren S, Bialik A, Mohsen J, Zaide Y, Hazan N, Ariel-Cohen O, Cohen R, Shitrit P, Marchaim D, Benenson S, Ben-David D, Rubinovitch B, Gotessman T, Nutman A, Wiener-Well Y, Maor Y, Carmeli Y, Cohen D. Sero-Prevalence and Sero-Incidence of Antibodies to SARS-CoV-2 in Health Care Workers in Israel, Prior to Mass COVID-19 Vaccination. Front Med (Lausanne). 2021 Jun 24;8:689994.

Goren S, Amir Y, Perlman S, Green MS, Chodick G, Cohen D. A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020-February 2021. Lancet Reg Health Eur. 2021 Aug;7:100130.


Clinical Study Protocols

"A Phase I Dose Escalation Study to Assess the Safety and Immunogenicity of the SF2a-TT15 Conjugate Vaccine against S. flexneri 2a in Healthy Adult Volunteers." 2015. Click here to view. 

אוניברסיטת תל אביב עושה כל מאמץ לכבד זכויות יוצרים. אם בבעלותך זכויות יוצרים בתכנים שנמצאים פה ו/או השימוש
שנעשה בתכנים אלה לדעתך מפר זכויות, נא לפנות בהקדם לכתובת שכאן >>